View : 421 Download: 0
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT
- Title
- Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT
- Authors
- Cho, Hee Jeong; Jung, Sung-Hoon; Jo, Jae-Cheol; Lee, Yoo Jin; Yoon, Sang Eun; Park, Sung-Soo; Kim, Do Young; Shin, Ho-Jin; Mun, Yeung-Chul; Yi, Jun Ho; Kim, Hyo Jung; Kim, Da Jung; Lee, Ho Sup; Bae, Sung Hwa; Hong, Chae Moon; Jeong, Shin Young; Min, Jung-Joon; Sohn, Sang Kyun; Min, Chang-Ki; Kim, Kihyun; Lee, Je-Jung; Moon, Joon Ho|Korean Multiple Myeloma Workin
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2021
- Journal Title
- BLOOD CANCER JOURNAL
- ISSN
- 2044-5385
- Citation
- BLOOD CANCER JOURNAL vol. 11, no. 12
- Publisher
- SPRINGERNATURE
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the Revised International Staging System (R-ISS) with FL, we analyzed the data of 380 patients with newly diagnosed MM (NDMM) who underwent F-18-fluorodeoxyglucose (F-18-FDG) PET/CT upon diagnosis. The K-adaptive partitioning algorithm was adopted to define subgroups with homogeneous survival. The combined R-ISS with PET/CT classified NDMM patients into four groups: R-ISS/PET stage I (n = 31; R-ISS I with FL <= 3), stage II (n = 156; R-ISS I with FL > 3 and R-ISS II with FL <= 3), stage III (n = 162; R-ISS II with FL > 3 and R-ISS III with FL <= 3), and stage IV (n = 31; R-ISS III with FL > 3). The 2-year overall survival rates for stages I, II, III, and IV were 96.7%, 89.8%, 74.7%, and 50.3%. The 2-year progression-free survival rates were 84.1%, 64.7%, 40.8%, and 17.1%, respectively. The new R-ISS/PET was successfully validated in an external cohort. This new system had a remarkable prognostic power for estimating the survival outcomes of patients with NDMM. This system helps discriminate patients with a good prognosis from those with a poor prognosis more precisely.
- DOI
- 10.1038/s41408-021-00577-2
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML